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Abstract
Background: The high in-hospital mortality of patients with cardiogenic shock is being
reduced thanks to coronary interventions. The aim of the study was to evaluate the outcomes of
angioplasty and stenting in patients with cardiogenic shock caused by left main coronary
artery (LMCA) disease.
Methods: A group of 71 consecutive patients managed for LMCA disease in an emergency
setting (38 patients in cardiogenic shock and 33 without shock symptoms) were followed up
clinically and angiographically for one year. Periprocedural and late mortality was assessed as
well as the incidence of restenosis and coronary re-interventions.
Results: There were 17 deaths in the study population (23.9%). One-year survival in the
subgroup with cardiogenic shock was 57.9% (22 patients) with 15 periprocedural deaths and
1 death 3 months after the procedure. Restenosis and associated target lesion revascularization
were documented in 5 patients (29.4%) with and 4 patients (16.0%) without cardiogenic
shock. Multivariate analysis revealed the following independent predictors of cardiogenic shock
in patients undergoing emergency LMCA angioplasty: STEMI as the reason for intervention
(OR 14.1; 95% CI 3.71–53.7; p < 0.0002) and a small minimal lumen diameter before the
procedure (OR 0.43; 95% CI 0.2–0.93; p < 0.04). The only independent predictor of the death
in patients with cardiogenic shock was a small minimal lumen diameter after the procedure
(OR 0.31; 95% CI 0.1–0.99, p < 0.05).
Conclusions: High mortality was observed in the study population, especially in the subgroup
with cardiogenic shock. Most deaths were periprocedural. Because of the high rate of restenosis,
periodical angiographic follow-up is necessary, preferably twice in the first 6 months after stent
implantation. (Cardiol J 2007; 14: 67–75)
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Introduction
Between 5% and 10% of cases of myocardial
infarction (MI) are complicated by cardiogenic
shock and this percentage has not changed in the
past 30 years. In prognosis is very serious in pa-
tients medically treated, with mortality of 70% to
80% [1]. As the SHOCK trial has demonstrated, the
overall mortality in shock, thanks to interventional
treatment, has been reduced by 9% and the 30-day
mortality dropped by 17% [2].
According to the current recommendations of
the European Society of Cardiology (ESC), imme-
diate interventional treatment (PCTA, percutane-
ous transluminal coronary angioplasty or CABG,
coronary artery bypass grafting) is necessary to
save lives, and in its absence thrombolytic therapy
must be initiated. The current ESC guidelines have
placed emergency percutaneous coronary interven-
tion (PCI) in patients with cardiogenic shock with-
in the class of recommendation I and the level of
evidence C [3]. In the case of patients with cardio-
genic shock, ESC recommendations differ with re-
spect to three vessel disease: percutaneous revas-
cularisation in several arteries may be performed
in certain situations. Also the 12-hour criterion from
the onset of pain to invasive treatment does not hold
in the case of patients with cardiogenic shock. In-
tra-aortic balloon pump (IABP) is recommended [4].
In the ACC/AHA/SCAI guidelines from 2005 [5],
class I (level of evidence A) includes primary PCI
for patients less than 75 years old with ST elevation
or left bundle branch block who develop cardiogenic
shock within 36 h of the onset of myocardial pain and
are suitable for revascularization within 18 h of shock.
In the case of patients over the age of 75 with car-
diogenic shock who meet the above criteria, recom-
mendations to perform primary PCI are placed in
class IIA (level of evidence B). Also according to the
US guidelines, it is beneficial to use IABP (if the
shock cannot be pharmacologically controlled). In pa-
tients with significant left main coronary artery
(LMCA) stenosis and three-vessel disease, without
right ventricular MI and co-morbidities that increase
the perioperative risk, such as renal failure or severe
pulmonary disease, the authors of the ACC/AHA/
/SCAI guidelines recommend CABG (class I). If
CABG cannot be performed, they recommend PCI.
Methods
Study population
We analysed clinical and angiographic data of
a group of 71 consecutive patients undergoing
emergency LMCA angioplasty between August
2001 and March 2005 at the Clinic of Cardiology and
Internal Medicine of the University Hospital in
Bydgoszcz, Poland. All the patients received bare
metal stents. Thirty-eight patients (53.5%) were in
cardiogenic shock.
Following the procedure all the surviving pa-
tients were started on long-term clopidogrel or ticlo-
pidine for 3 to 12 months and long-term acetylsali-
cylic acid, an angiotensin converting enzyme inhibi-
tor, a cardioselective beta-blocker and a statin.
Fifty-four patients (including 22 patients in car-
diogenic shock) who survived the procedure and the
periprocedural period were followed up clinically for
1 year. They also underwent follow-up angiographies
at 3, 6 and 12 months to check for restenosis.
The retrospective analysis of the treatment
outcomes in this group of patients was approved by
the Bioethics Committee of the Medical College in
Bydgoszcz, Nicolaus Copernicus University in
Toruń (KB/79/2006).
Angiographic analysis
All the patients who gave their consents un-
derwent follow-up coronary angiographies. During
the procedure and the follow-up examinations we
used Integris CV Allura (Philips) with digital image
processing. We selected one view which best rep-
resented the left main coronary artery. Then, us-
ing the commonly known quantitative angiography
system [6] employing the Philips software Quanti-
tative coronary analysis. Inturis for cardiology. Ver-
sion 1.1, we obtained the results of quantitative
analysis calculated by the computer. Restenosis was
defined as a narrowing of 50% or more of the ves-
sel lumen within the stent and 5 mm proximally or
distally from the stent.
Observation and statistical analysis
During the follow-up period we analysed major
adverse cardiac events (MACE), such as death, MI,
emergency revascularisation and restenosis as well
as the target vessel revascularisation (TVR) of the
left main coronary artery. In order to evaluate the
risk of death and/or MACE and the perioperative risk
we used the TIMI Risk Score and the EuroSCORE.
The calculations were performed using the sta-
tistical software Statistica version 7.1 PL (StatSoft,
Tulsa, USA).
The W Shapiro-Wilk test demonstrated that the
distribution of the analysed quantitative variables
was not normal. They were therefore presented as
median values and quartile intervals. Median val-
ues of two quantitative variables were compared
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using the Mann-Whitney test. Qualitative variables
were presented as the number of patients with
a given trait and a percentage in the group. Qualita-
tive variables were compared using the c2 test or the
exact Fisher test, depending on the size of the groups.
The multivariate logistic regression model was
used for the multivariate analysis of the effect of the
qualitative and quantitative variables on the binary
variable. The relationships between the increase of
the quantitative variables or variants of the quali-
tative variables and the probability of an endpoint
were presented by providing the odds ratio (OR)
and the limits of its 95% confidence interval (CI).
P values of less than 0.05 were considered sta-
tistically significant. P values falling between 0.05
and 0.10, which represented a trend towards sta-
tistical significance, were provided in their exact
values. P values exceeding 0.10, being not signifi-
cant, were replaced by the abbreviation NS. The
abbreviation UF (unfeasible) denotes the absence
of possibility to perform the analysis due to failure
to meet the assumptions for the test.
Results
Analysis of outcomes for all the patients
undergoing emergency PCI
The characteristics of patients with cardiogenic
shock versus the remaining patients undergoing
emergency treatment are presented in Table 1.
In the group of 71 patients undergoing emer-
gency treatment there were 17 deaths, 16 of which
occurred in patients with cardiogenic shock. The
between group differences, both in respect of the
overall number of deaths and the number of peripro-
cedural deaths, are statistically significant (Table 2).
Table 1. A comparison of clinical data for the groups of patients with and without cardiogenic shock
undergoing emergency left main coronary artery angioplasty.
Parameter Patients with Patients without p
cardiogenic shock cardiogenic shock
(n = 38) (n = 33)
Age [years] 65.0 (55.0–75.0) 63.0 (53.0–70.0) NS
Gender: NS
female 15 (39.5%) 10 (30.3%)
male  23 (60.5%) 23 (69.7%)
Diabetes 19 (50.0%) 12 (36.4%) NS
Hypertension 23 (85.4%) 22 (66.7%) NS
Hyperlipidaemia 34 (89.5%) 31 (93.9%) NS
Smoking status:
current smoker 13 (34.2%) 4 (12.1%) 0.058
current or past smoker  24 (63.2%)   19 (57.6%) NS
Positive family history 7 (18.4%) 8 (24.2%) NS
Peripheral artery disease 7 (18.4%) 7 (21.2%) NS
History of stroke 6 (15.8%) 6 (18.2%) NS
Creatinine [mg/dl] 1.2 (1.1–1.4) 1.2 (1.0–1.3) NS
Left ventricular ejection fraction [%] 40.0 (30.0–45.0) (n = 29) 45.0 (35.0–51.0) (n = 33) NS
EuroSCORE 9.0 (7.0–11.0) 7.0 (5.0–11.0) 0.060
TIMI Risk Score UA/NSTEMI 4.0 (3.5–4.5) 4.0 (3.0–4.0) NS
TIMI Risk Score STEMI 6.0 (5.0–9.0) 4.0 (3.0–5.0) < 0.0002
Angioplasty of distal vs. other stenoses; UA — unstable angina; STEMI — ST-elevation myocardial infarction; NSTEMI — non-ST-elevation myocar-
dial infarction; NS — not significant
Table 2. Deaths in the groups of patients with cardiogenic shock and the other patients receiving
emergency treatment.
Parameter Patients with cardiogenic Patients without cardiogenic p
shock (n = 38)  shock (n = 33)
All deaths 16 (42.1%) 1 (3.0%) < 0.0005
Periprocedural deaths 15 (39.5%) 1 (3.0%) < 0.0008
Deaths during follow-up 1 (2.6%) 0 (0%) Unfeasible
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Of the 38 patients undergoing LMCA angioplasty
in cardiogenic shock, 22 (57.9%) survived
12 months. There were 15 periprocedural deaths
and one death during the follow-up period (3 months
after the procedure, due to respiratory failure).
Among the patients with cardiogenic shock, the
reason for LMCA angioplasty was non-ST-elevation
acute coronary syndrome in 4 cases (10.5%) and
ST-elevation myocardial infarction (STEMI) in
34 cases (89.5%). In the group without cardiogenic
shock, 19 patients (57.6%) were managed for unsta-
ble angina (UA) or non-ST-elevation myocardial in-
farction (NSTEMI) and 14 patients (42.4%) received
treatment for STEMI. Patients managed for non-ST-
-elevation acute coronary syndromes were patients
ineligible for cardiac surgery due to co-morbidities
or serious general condition and patients who refused
surgery. The larger number of patients with STEMI
in the group with cardiogenic shock is not statisti-
cally significant versus the group of patients with-
out cardiogenic shock: p < 0.0002 (Fig. 1). Of note
is the fact that among the patients with STEMI,
the group with cardiogenic shock revealed a sig-
nificantly higher TIMI Risk Score (median 6.0,
range 5.0–9.0) than the group without cardiogenic
shock (median 4.0, range 3.0–5.0, p < 0.0002).
Eleven patients (28.9%) with cardiogenic shock
and 1 patient (3.0%) without cardiogenic shock were
resuscitated prior to admission to the Invasive Car-
Figure 1. Reason for left main coronary artery angiopla-



















Unstable angina/non−ST−elevation myocardial infarction
diology Suite. The difference between the groups
was statistically significant (p < 0.01). Nine patients
(23.7%) with cardiogenic shock and only 1 patient
(3.0%) without cardiogenic shock were unconscious
during LMCA angioplasty. This difference was also
significant (p < 0.04).
Eight patients with cardiogenic shock (21.0%)
and none without cardiogenic shock underwent in-
tra-aortic balloon pumping. The statistical analysis
was not performed because of the failure to meet
the test assumptions.
An inhibitor of platelet GP IIb/IIIa receptors
was administered significantly more frequently to
patients in cardiogenic shock (p < 0.004) and was
received by 30 patients with cardiogenic shock
(78.9%) and 15 patients without cardiogenic shock
(45.4%). The analysis included angiographic data for
groups of patients with and without cardiogenic
shock who received emergency treatment (Table 3).
Restenosis was analysed in the group of pa-
tients who survived and gave consent for follow-up
coronary angiography. Follow-up coronary angiogra-
phy was performed in 17 patients with cardiogenic
shock. One of the patients in this group, who previ-
ously refused consent for elective examinations, un-
derwent emergency angiography at 3 months and was
also included in the analysis. Follow-up coronary an-
giography was performed in 25 patients without car-
diogenic shock. Restenosis and target lesion revas-
cularization occurred in 5 patients (29.4%) with car-
diogenic shock and in 4 patients (16.0%) without
cardiogenic shock. The difference was not significant.
Restenosis was observed in at 3 months in 7 cases, at
6 months in 1 case and at 7 months in 1 patient who
did not attend the earlier follow-up angiography.
The group of patients with cardiogenic shock
was characterised by a significantly lower LMCA
minimal lumen diameter (MLD) before the proce-
dure than the group without shock (Table 3). The
difference was statistically significant (p < 0.005).
In multivariate analysis, STEMI as the reason
for the procedure and low MLD before the proce-
dure were revealed as independent predictors of
cardiogenic shock in patients undergoing emergen-
cy LMCA angioplasty (Table 4).
Analysis of deaths in patients
with cardiogenic shock
The group of patients who survived the follow-up
period and the group of patients who died did not
differ significantly in terms of age, gender and cause
of shock (Table 5).
The analysis of ischaemic heart disease risk
factors present in patients with cardiogenic shock
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Table 3. Angiographic characteristics of patients managed in cardiogenic shock and the remaining
patients receiving emergency treatment.
Parameter Patients with cardiogenic Patients without P
shock (n = 38) cardiogenic shock (n = 33)
Location of the stenosis within LMCA:
proximal 10 (26.3%) 5 (15.2%)
middle 5 (13.2%) 7 (21.2%)
distal 22 (57.9%) 21 (63.6%) NS*
diffuse 1 (2.6%) 0 (0%)
Coronary arteries affected:
LMCA only 5 (13.2%) 3 (9.0%) NS
LMCA + 1 vessel 9 (23.7%) 7 (21.3%) NS
LMCA + multiple vessels    24 (63.1%) 23 (69.7) NS
Drug eluting stent 0 (0%) 0 (0%) Unfeasible
Angiographic restenosis 5 (29.4%) (n = 17) 4 (16.0%) (n = 25) NS
No consent for angiographic follow-up** 6 (27.3%) 7 (21.9%) NS
Interventions in another artery during 5 (22.7%) (n = 22) 10 (31.2%) (n=32) NS
the follow-up**
Reference diameter [mm] 3.53 (3.17–4.36) 3.99 (3.17–4.34) NS
Reference area [mm2] 9.61 (7.75–14.94) 12.50 (7.90–14.82) NS
MLD before the procedure [mm] 0.77 (0.28–1.15) 1.29 (0.62–1.87) < 0,005
MLA before the procedure [mm2] 0.46 (0.06–1.03) 1.30 (0.31–2.76) < 0,005
MLD after the procedure [mm] 3.42 (3.20–3.96) 3.67 (3.24–4.03) NS
MLA after the procedure [mm2] 9.18 (8.04–12.31) 10.60 (8.24–12.73) NS
*Angioplasty of distal vs. other stenoses; **The percentage was calculated in the group of patients who survived until at least the first follow-up coronary
arteriography; LMCA — left main coronary artery; MLD — minimal lumen diameter; MLA — minimal lumen area; NS — not significant
Table 4. Predictors of cardiogenic shock.
Trait Variant of the trait Odds ratio 95% confidence interval P
Reason for the procedure STEMI 14.11 3.71–53.70 < 0.0002
NSTEMI/UA  1
MLD before the procedure MLD increase before 0.43 0.20–0.93 < 0.04
the procedure by 1 mm
MLD — minimal lumen diameter; STEMI — ST-elevation myocardial infarction, NSTEMI — non-ST-elevation myocardial infarction, UA — unstable angina
did not reveal any significant effect on death in this
group of patients.
We then analysed angiographic data of patients
who survived and of patients who died (Table 6).
In the group of patients who died, dimensions in the
reference segment and the LMCA MLD before and
after the procedure were lower. Statistical signifi-
cance was, however, present only in the case of the
reference segment dimension and the postproce-
dural MLD.
In multivariate analysis, the only independent
predictor of death in patients with cardiogenic shock
was low postprocedural MLD (OR 0.31; 95% CI
0.1–0.99; p < 0.05).
Discussion
The SHOCK trial has proved that revasculari-
sation in patients with cardiogenic shock reduces
in-hospital mortality [7, 8]. Still, however, despite
the interventional treatment, in-hospital mortality
in this group of patients remains high [9].
Multivariate analysis demonstrated that the
independent predictors of cardiogenic shock in pa-
tients undergoing emergency LMCA angioplasty
were STEMI as the reason for the procedure and
low MLD in coronary angiography performed be-
fore the procedure. Reduced LMCA lumen diame-
ter is responsible for impaired myocardial perfusion.
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The lower the diameter, the more ischaemic the
myocardium and the critical stenosis or total occlu-
sion of LMCA leads to death or cardiogenic shock.
It is therefore obvious that a low MLD before the
procedure is an independent predictor of cardiogen-
ic shock in patients undergoing emergency treat-
ment for left main disease.
STEMI occurred in 89.5% of patients with car-
diogenic shock, while in the group of patients un-
dergoing emergency treatment without cardiogen-
ic shock, non-ST-elevation acute coronary syn-
dromes prevailed (57.6%). This is consistent with
the following regularity established a long time ago:
in most cases of acute LMCA occlusion, if the
patient does not die a sudden death, he develops
cardiogenic shock. Prognosis in such situations is
very grave: 94% of patients managed conservatively
die [10]. Initiation of interventional treatment im-
proves the prognosis.
In the group of patients with cardiogenic shock,
compared to the remaining patients receiving emer-
gency treatment, there were significantly more pa-
tients who had been resuscitated before or during
admission to the Invasive Cardiology Suite and pa-
tients who were unconscious during PCI. These cir-
cumstances, however, did not affect the incidence of
Table 6. Parameters of quantitative angiography in patients with cardiogenic shock who survived and
who died.
Parameter Patients who survived (n = 22) Patients who died (n = 16) p
Reference diameter [mm] 3.57 (3.41–4.35) 3.41 (2.02–4.60) < 0.05
Reference area [mm2] 9.80 (8.17–14.89) 9.15 (3.22–16.70) < 0.05
MLD before the procedure [mm] 0.86 (0.29–1.18) 0.50 (0.16–0.96) NS
MLA before the procedure [mm2] 0.57 (0.07–1.10) 0.19 (0.02–0.73) NS
MLD after the procedure [mm] 3.76 (3.38–3.99) 3.06 (2.58–3.44) < 0.02
MLA after the procedure [mm2] 11.12 (8.98–12.47) 7.40 (5.26–9.29) < 0.02
MLD — minimal lumen diameter; MLA — minimal lumen area
Table 5. Clinical characteristics of the patients undergoing left main coronary artery angioplasty in car-
diogenic shock.
Parameter Patients who survived Patients who died p
(n = 22)  (n = 16)
Age [years] 64.0 (55.0–75.0) 65.0 (54.5–75.5) NS
Gender:
female 10 (45.5%) 5 (31.2%) NS
male   12 (54.5%)   11 (68.7%)
Cause of shock:
UA/NSTEMI 2 (9.1%) 2 (12.5%) NS
STEMI 20 (90.9%) 14 (87.5%)
TIMI Risk Score UA/NSTEMI 3 and 4 4 and 5 UF
TIMI Risk Score STEMI 5.5 (5.0–7.5) 7.5 (6.0–9.0) 0.060
EuroSCORE 9.0 (8.0–10.0) 8.5 (7.0–11.5) NS
After resuscitation 5 (22.7%) 6 (37.5%) NS
Unconscious during PCI 3 (13.6%) 6 (37.5%) NS
Intra-aortic balloon pump 2 (9.1%) 6 (37.5%) 0.086
Use of GP IIb/IIIa antagonist 15 (68.2%) 15 (93.7%) NS
Protected LMCA 0 (0%) 1 (6.2%) UF
Location of the stenosis within LMCA:
proximal 4 (18.2%) 6 (37.5%)
middle 2 (9.1%) 3 (18.7%)
distal 15 (68.2%) 7 (43.8%) 0.071*
diffuse 1 (4.5%) 0 (0%)
*Angioplasty of distal vs. other stenoses; LMCA — left main coronary artery; PCI — percutaneous coronary intervention; UA — unstable angina;
STEMI — ST-elevation myocardial infarction; NSTEMI — non-ST-elevation myocardial infarction; NS — not significant,  UF — unfeasible
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death in this group of patients, which supports the
importance of rapid PCI as a life-saving procedure.
The TIMI Risk Score provides information on
the severity of prognosis in shock [11, 12]. In the
study population, the median score in the group
with STEMI and cardiogenic shock was 6.0 (range:
5.0–9.0) and, quite understandably, was significantly
higher than the median score in MI patients with-
out cardiogenic shock (median: 4.0, range: 3.0–5.0).
The difference in the TIMI score between the pa-
tients who had died and those who had survived was
nearly significant (p = 0.06). This points to the pos-
sible usefulness of this scale in prognosing the risk
in patients with STEMI and cardiogenic shock. No
similar relationships could be demonstrated in the
group with cardiogenic shock in the course of
non-ST-elevation acute coronary syndromes, which is
a result of the very small sample size. According to
the predicted operative risk scale EuroSCORE [13],
all patients receiving emergency treatment were at
a high operative risk. Although the difference in the
score between the groups with and without cardio-
genic shock demonstrated a trend towards statisti-
cal significance, the groups of patients with shock
who had died and who had survived did not differ
significantly. It therefore seems that this scale is
difficult to use for prognosis in this group of patients.
The in-hospital mortality rate was 39.5% in the
study group of patients with cardiogenic shock and
3% in the group of patients with acute coronary
syndromes without cardiogenic shock. During the
12 months of follow-up there was 1 non-cardiac
death in the group of patients with shock and no
deaths in the group of patients without cardiogenic
shock. The one-year survival in the group of pa-
tients with cardiogenic shock undergoing LMCA
angioplasty was therefore 57.9%. This result is
comparable to or slightly better than the few results
published by other centres, concerning treatment
of small groups of patients with cardiogenic shock
managed for LMCA disease with angioplasty and
stenting [14–17]. In the ULTIMA register [18], the
one-year mortality rate in patients managed during
cardiogenic shock was as much as 67.6%. One
should, however, remember that not all of the
37 analysed patients underwent stenting during PCI.
Also with respect to mortality in patients with
cardiogenic shock who underwent CABG [8] the
results obtained in the study are favourable. There
is a need for large randomised trials comparing the
outcomes of PCI and CABG in patients with LMCA
disease who are in cardiogenic shock. Cardiac sur-
gery may be superior to angioplasty in cardiogenic
shock because of the protection of ischaemic
myocardium provided by cardioplegia, reduced ven-
tricular workload during the procedure and revas-
cularisation in the non-infarct areas. Immediate
access to the operating theatre is, however, not al-
ways possible. As demonstrated in the SHOCK tri-
al [8], time since MI pain to the beginning of PCI
was significantly shorter (p < 0.001) with the me-
dian of 11.0 h (range: 6.1–21.4 h) than time to CABG
(median: 19.1 h, range: 10.4–30.5 h).
It therefore seems that coronary angioplasty
and stenting, where the cause of shock is LMCA
disease, is the treatment of choice due to the high-
er availability and shorter time to treatment. In the
case of patients during resuscitation, this is the only
option of interventional treatment.
In the study group, pharmacological treatment of
shock (dopamine, dobutamine or adrenaline in con-
tinuous intravenous infusion) was used in all patients.
Intra-aortic balloon pumping was used in 21% of pa-
tients in cardiogenic shock (8 patients) and was not
found to reduce mortality in this group of patients:
2 patients who underwent IABP survived and 6 died.
It is hard to evaluate this result, as the group in
which IABP was used was small due to the period-
ic limitation of availability of the device, especially
between 2001 and 2003. In their study, Yamane et
al. [16] used IABP in all the 25 patients, in addition
to drug therapy of shock. The 30-day mortality was
lower (32%) than the mortality we observed, but
the 12-month mortality was comparable (40%).
With the currently more frequent use of counter-
pulsation, the immediate outcomes of patients with
LMCA stenosis in cardiogenic shock may improve.
Several studies of small groups of patients with
cardiogenic shock have been published that suggest
the presence of beneficial effect of a platelet GP IIb/IIIa
receptor antagonist on mortality in these patients
[19–21]. In our study, however, the significantly
more frequent use of a platelet GP IIb/IIIa receptor
antagonist did not significantly reduce mortality in
this group of patients. This may result from the fact
that most of the deaths in patients with shock oc-
curred within a short time of initiation of treatment,
still at the Invasive Cardiology Suite, and the dura-
tion of action of the drug was too short. Furthermore,
not all the patients with and without shock were man-
aged in this way, which makes it even more difficult
to perform the comparison and draw conclusions.
The analysis of quantitative angiography results
for patients treated in cardiogenic shock demonstrat-
ed significant differences in the reference segment
diameter and MLD after the procedure: in the group
of patients who had died, they were lower than in the
group of patients who had survived. Multivariate
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analysis demonstrated low MLD after the procedure
to be the only independent predictor of death in pa-
tients with cardiogenic shock, similarly to the patient
groups previously presented by Black et al. [22] and
Park et al. [23], although these studies did not include
patients with cardiogenic shock. The outcome of cor-
onary angioplasty does affect the prognosis. It is im-
portant to achieve a lumen increase, over a short pe-
riod of time, which largely depends on the anatomy
of the vessels, the operator’s experience and tech-
niques of plaque decompression and stenting.
Limitations of the study
The study is an analysis of 71 patients without
randomisation. The evaluation is impeded by the
lack of patient consent for the follow-up coronary
arteriography, which the patients justified by the
absence of anginal symptoms and good well being.
For this reason one cannot estimate the exact ang-
iographic restenosis rate. It was also impossible to
take a full history form some of the patients due to
the grave condition of many of them on admission
(unconscious patients, patients after resuscitation,
patients with seriously impaired consciousness) and
the considerable number of periprocedural deaths.
Conclusions
Despite the routine use of stents, LMCA angi-
oplasties in patients undergoing emergency treat-
ment for acute coronary syndromes continue to be
associated with high mortality with patients in car-
diogenic shock being at the highest risk. Deaths
most frequently occur periprocedurally. Due to the
continuing high restenosis rate it is necessary to
perform periodic follow-up angiographies, prefera-
bly twice in the first 6 months after the procedure.
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